Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1169
Abstract: This cohort study assesses whether treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is associated with better outcomes than treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes and advanced-stage chronic kidney disease… read more here.
Keywords: dipeptidyl peptidase; kidney; glucagon like; kidney disease ... See more keywords
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.14493
Abstract: Key Points Question Among adults with type 2 diabetes (T2D), what is the efficacy, safety, and tolerability of the novel, orally administered, small molecule glucagon-like peptide 1 receptor agonist danuglipron? Findings In this phase 2… read more here.
Keywords: efficacy safety; like peptide; peptide receptor; glucagon like ... See more keywords
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.16290
Abstract: This cohort study compares rates of 1-year adherence to glucagon-like peptide-1 receptor agonist or sodium-glucose cotransporter 2 inhibitor therapies by co-payment level among US adults with type 2 diabetes and/or heart failure. read more here.
Keywords: agonist sodium; peptide receptor; glucagon like; adherence glucagon ... See more keywords
Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "ChemMedChem"
DOI: 10.1002/cmdc.201700781
Abstract: Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose‐dependent insulin secretion. Further, GLP‐1 is also associated with protective effects… read more here.
Keywords: peptide; glucagon like; glp; peptide glp ... See more keywords
A novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Comparative Neurology"
DOI: 10.1002/cne.24905
Abstract: Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone with a number of functions to maintain energy homeostasis and contribute to motivated behavior, both peripherally and within the central nervous system (CNS). These functions, which include insulin… read more here.
Keywords: glucagon like; expression; receptor; brain ... See more keywords
Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Obesity"
DOI: 10.1002/oby.23622
Abstract: Weight loss achieved with standard doses of glucagon‐like peptide‐1 (GLP‐1) agonists among real‐world patients with type 2 diabetes has not been determined. This study sought to describe the percent change in body weight 72 weeks after… read more here.
Keywords: patients type; agonists among; glucagon like; like peptide ... See more keywords
GUB06‐046, a novel secretin/glucagon‐like peptide 1 co‐agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Peptide Science"
DOI: 10.1002/psc.3048
Abstract: Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight‐lowering effects of bariatric surgery involve stimulated secretion of… read more here.
Keywords: glucagon like; mass; mice; gub06 046 ... See more keywords
Insulin‐like peptide 3 in domestic animals with normal and abnormal reproductive functions, in comparison to rodents and humans
Sign Up to like & getrecommendations! Published in 2022 at "Reproductive Medicine and Biology"
DOI: 10.1002/rmb2.12485
Abstract: Insulin‐like peptide 3 (INSL3) is a circulating hormone secreted from only testis and ovaries in mammals. Findings on INSL3 have been gathered from subjects with normal and abnormal reproductive statuses, especially rodents and humans. However,… read more here.
Keywords: rodents humans; insulin like; like peptide; domestic animals ... See more keywords
Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice
Sign Up to like & getrecommendations! Published in 2021 at "Brain Structure and Function"
DOI: 10.1007/s00429-021-02380-y
Abstract: Glucagon-like peptide 1 (GLP-1) and its agonists exert anorexigenic effect at least partly via acting on GLP-1 receptors (GLP-1R) in the arcuate nucleus (ARC). While the anorexigenic, proopiomelanocortin (POMC) neurons of the ARC were shown… read more here.
Keywords: like peptide; glp; glucagon like; npy neurons ... See more keywords
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-1051-2
Abstract: Purpose of ReviewMimetics and analogs that extend the half-life of native glucagon-like peptide-1 (GLP-1), i.e., glucagon-like peptide-1 receptor agonists (GLP-1 RAs), at therapeutic doses, are indicated as adjuncts to diet and exercise, to improve glycemic… read more here.
Keywords: reduction; risk; glucagon like; glp ras ... See more keywords
Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01637-6
Abstract: The present study aimed to evaluate the effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on clinical and safety outcomes including glycemic control and cardiometabolic indicators using network meta-analysis. MEDLINE, Embase, and Cochrane Library Central… read more here.
Keywords: network meta; safety; glucagon like; like peptide ... See more keywords